Now, a significant update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology is ...
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England ...
For patients with stage III melanoma, the median duration of distant metastasis-free survival was more than 9 years and 83.8 months with nivolumab and ipilimumab, respectively. HealthDay News — For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results